GoodRx (NASDAQ:GDRX) Shares Up 2.8% Following Analyst Upgrade

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price rose 2.8% during trading on Tuesday after Barclays raised their price target on the stock from $9.00 to $10.00. Barclays currently has an overweight rating on the stock. GoodRx traded as high as $7.54 and last traded at $7.33. Approximately 438,661 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 1,549,539 shares. The stock had previously closed at $7.13.

GDRX has been the topic of several other reports. UBS Group lifted their price target on shares of GoodRx from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, March 1st. Raymond James raised shares of GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Thursday, May 16th. Royal Bank of Canada boosted their price objective on shares of GoodRx from $7.00 to $8.00 and gave the company a “sector perform” rating in a report on Friday, March 1st. SVB Leerink started coverage on shares of GoodRx in a research report on Monday, February 26th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Wells Fargo & Company upgraded shares of GoodRx from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $7.50 to $10.00 in a research report on Monday, March 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Institutional Trading of GoodRx

Several institutional investors and hedge funds have recently modified their holdings of the business. Beacon Capital Management LLC purchased a new stake in shares of GoodRx in the first quarter valued at about $28,000. California State Teachers Retirement System lifted its stake in shares of GoodRx by 5.1% during the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after buying an additional 3,444 shares during the period. EntryPoint Capital LLC lifted its stake in shares of GoodRx by 165.2% during the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after buying an additional 11,548 shares during the period. Jupiter Asset Management Ltd. purchased a new position in shares of GoodRx during the first quarter valued at approximately $707,000. Finally, Picton Mahoney Asset Management purchased a new position in shares of GoodRx during the first quarter valued at approximately $3,467,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Stock Up 0.4 %

The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. The firm’s 50-day moving average is $6.95 and its 200 day moving average is $6.51. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of -716.00, a price-to-earnings-growth ratio of 3.05 and a beta of 1.37.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. The firm had revenue of $196.64 million during the quarter, compared to analyst estimates of $195.59 million. Sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.23 earnings per share for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.